Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)

 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Stage 1 demo of ETX-155 for major depressive condition (MDD) and epilepsy. 
...
